REC-4881 Phase 2 in FAP: 53% median polyp burden cut at week 25
Recursion reported results from its Phase 2 study of REC-4881 for familial adenomatous polyposis on May 6, 2026. The study met its main goal.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary
- Company
- Recursion Pharmaceuticals, Inc. RXRX
- Drug
- REC-4881
- For
- familial adenomatous polyposis
- Stage
- Phase 2 · the stage that tests whether the drug actually works
- When
- May 6, 2026
- Source note
- Recursion disclosed Phase 2 proof-of-concept TUPELO data for MEK1/2 inhibitor REC-4881 in familial adenomatous polyposis — median 43% polyp burden reduction at Week 13 deepening to 53% at Week 25, 40% of patients improving Spigelman stage — and said FDA discussions on a registrational path had begun. Disclosed within the Q1 2026 business update; no standalone release was issued.
- Checked
- Checked by a person when it was added
- Source: sec.gov ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- RXRX headlines on this site
REC-4881 FDA registrational-path update in FAP, expected in the second half of 2026 (no exact date yet). A company milestone for Recursion (REC-4881 (MEK1/2 inhibitor) for familial adenomatous polyposis): a step in the program rather than a decision or a data readout.
More details
- Entry
- REC-4881 FDA registrational-path update in FAP · Company milestone
- Drug
- REC-4881 (MEK1/2 inhibitor)
- For
- familial adenomatous polyposis
- Stage
- Phase 2 · the stage that tests whether the drug actually works
- When
- H2 2026 · the company gave a window, not a day
- Source note
- "Discussions with FDA were initiated in 1H26 and an update to define the registrational path is expected in 2H26."
- Checked
- Checked by a person when it was added
- Verify it
- Source: biospace.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- RXRX headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Recursion expects to report results from its Phase 1 study of REC-1245 (RBM39 degrader) for biomarker-enriched solid tumors and lymphoma in the second half of 2026 (no exact date yet). Phase 1 is an early safety study in a small group of people.
More details
- Entry
- REC-1245 Phase 1 dose-escalation data · Clinical trial results (readout / topline data)
- Drug
- REC-1245 (RBM39 degrader)
- For
- biomarker-enriched solid tumors and lymphoma
- Stage
- Phase 1 · an early safety study in a small group of people
- When
- H2 2026 · the company gave a window, not a day
- Source note
- "Additional Phase 1 dose escalation data expected in 2H26."
- Checked
- Checked by a person when it was added
- Verify it
- Source: biospace.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- RXRX headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
REC-7735 PI3Ka H1047R inhibitor Phase 1/2 start in solid tumors, expected in the second half of 2026 (no exact date yet). A company milestone for Recursion (REC-7735 for PI3Ka H1047R-mutant solid tumors): a step in the program rather than a decision or a data readout.
More details
- Entry
- REC-7735 PI3Ka H1047R inhibitor Phase 1/2 start in solid tumors · Company milestone
- Drug
- REC-7735
- For
- PI3Ka H1047R-mutant solid tumors
- Stage
- Phase 1/2 · an early study that checks safety and takes a first look at effect
- When
- H2 2026 · the company gave a window, not a day
- Source note
- Q2 2026 results PR (Aug 5, 2026): IND for AI-designed REC-7735 cleared; Phase 1/2 trial in select solid tumors expected to start in the second half of 2026.
- Checked
- Checked by a person when it was added
- Verify it
- Source: biospace.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- RXRX headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Recursion presents data on REC-4881 (MEK1/2 inhibitor) for familial adenomatous polyposis at a medical meeting on Nov 2, 2026. New numbers at a conference can move the stock as much as a formal announcement.
More details
- Entry
- REC-4881 TUPELO FAP data in Presidential Plenary at CGA-IGC (Nov 2) · Data presented at a medical meeting
- Drug
- REC-4881 (MEK1/2 inhibitor)
- For
- familial adenomatous polyposis
- Stage
- Phase 2 · the stage that tests whether the drug actually works
- When
- Nov 2, 2026
- Source note
- more precise date for existing RXRX|conference|2026-11 item. Q2 2026 PR says additional TUPELO Phase 2 safety/efficacy data contextualized with real-world data will be presented at CGA-IGC Annual Meeting, Presidential Plenary I, Nov 2, 2026. FDA registrational-path update still guided for 2H26.
- Checked
- Checked by a person when it was added
- Verify it
- Source: biospace.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- RXRX headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Recursion expects to report results from its Phase 1 study of REC-617 (CDK7 inhibitor) for advanced solid tumors in the first half of 2027 (no exact date yet). Phase 1 is an early safety study in a small group of people.
More details
- Entry
- REC-617 Phase 1 combination safety/PK data · Clinical trial results (readout / topline data)
- Drug
- REC-617 (CDK7 inhibitor)
- For
- advanced solid tumors
- Stage
- Phase 1 · an early safety study in a small group of people
- When
- H1 2027 · the company gave a window, not a day
- Source note
- "Early Phase 1 safety and PK combination data expected in 1H27."
- Checked
- Checked by a person when it was added
- Verify it
- Source: biospace.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- RXRX headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Recursion expects to report results from its Phase 1 study of REC-3565 (MALT1 inhibitor) for B-cell malignancies in the first half of 2027 (no exact date yet). Phase 1 is an early safety study in a small group of people.
More details
- Entry
- REC-3565 Phase 1 monotherapy safety/PK data · Clinical trial results (readout / topline data)
- Drug
- REC-3565 (MALT1 inhibitor)
- For
- B-cell malignancies
- Stage
- Phase 1 · an early safety study in a small group of people
- When
- H1 2027 · the company gave a window, not a day
- Source note
- "Early Phase 1 safety and PK monotherapy data expected in 1H27."
- Checked
- Checked by a person when it was added
- Verify it
- Source: biospace.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- RXRX headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page